Early Detection of Growth Disorders With the CrescNet System at the Leipzig Treatment Center

Wolfgang Hoepffner, Roland Pfäffle, Ruth Gausche, Christof Meigen, Eberhard Keller

SUMMARY

Background: Growth hormone replacement therapy is more effective the earlier it is begun. This article addresses the question whether children with growth hormone deficiency (GHD) were able to begin treatment earlier through the use of the CrescNet system in the Department of Pediatrics at the Leipzig University Hospital. CrescNet is a network of pediatricians and endocrinological treatment centers, established in Leipzig in 1998, whose aim is to improve the early detection of growth disorders.

Methods: Pediatricians participating in CrescNet provided anonymized data on their patients' height and weight to the CrescNet database. Each participating pediatrician received a quarterly screening report with recommendations for the work-up of children with abnormal growth. Some patients with GHD who were treated in the Leipzig treatment center were referred in response to these recommendations, while others came spontaneously from the practices of pediatricians participating or not participating in CrescNet. We determined the age at the onset of treatment for the 139 patients treated for GHD in the University Children's Hospital Leipzig from 1999 to 2005 and compared the findings with data from other treatment centers in Germany.

Results: Patients from CrescNet practices began treatment at a younger age than those from non-CrescNet practices (8.77 ± 3.40 versus 9.50 ± 3.78 years, p = 0.26). Patients from CrescNet practices whose GHD was detected by screening began treatment earlier than those for whom no data had been sent (7.67 ± 3.21 versus 9.28 ± 3.39 years, p = 0.031). In the center in Leipzig, but not in other German GHD treatment centers, the age at onset of treatment dropped significantly over the period of the study and then remained steady till 2009 in the range of 7.61 ± 3.0 years.

Conclusion: These descriptive results imply that the linking of pediatricians' practices with the CrescNet system resulted in earlier treatment of children with GHD.

Cite this as:
Patients and methods

Partners in CrescNet can be any pediatrician and any family physician who provides basic care for children and adolescents. Measurements of height and weight are done by the participating doctors under standardized conditions. They are provided with uniform precision measuring instruments for height (17), funded by the project, and are trained in the measuring technique. The collected data are pseudonymized and sent for central analysis to the database which is maintained and administered by CrescNet gGmbH. All measurements are subject to plausibility checks.

Each CrescNet practice receives a screening report prepared by the responsible endocrinologists at about 3-monthly intervals from the start of their involvement to the present. This enables detection of any abnormalities in growth and weight development of the children and recommendations to be made on further actions to the pediatricians providing care. The pediatrician is either requested to provide any missing data, to take subsequent measurements at shorter intervals or, in cases of serious abnormalities, to immediately refer the child to a pediatric endocrinologist in a treatment center for an assessment. Patients were also referred from CrescNet practices if their growth and development data had not previously been sent to the CrescNet database. Patients also came from practices that are not associated with CrescNet.

The descriptive analysis covers the period from 1 January 1999 to 31 December 2005. The data of all children presenting to the University Children’s Hospital Leipzig with suspected growth disorders were retrospectively analyzed. Only those patients with a verified growth hormone deficiency were then selected for the present study. The inclusion criterion was a growth hormone peak of <10 µg/mL in two stimulation tests.

### TABLE 1

<table>
<thead>
<tr>
<th></th>
<th>GHD total (139)</th>
<th>Not a CrescNet partner</th>
<th>9.50 ± 3.78 (44)</th>
<th>p = 0.26</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>CrescNet partner</td>
<td>8.77 ± 3.40 (95)</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Patients without screening</td>
<td>9.28 ± 3.39 (65)</td>
<td></td>
<td>p = 0.031</td>
</tr>
<tr>
<td></td>
<td>Patients after screening</td>
<td>7.67 ± 3.21 (30)</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

The patients from non-CrescNet partners began therapy later than those from CrescNet partners. The age at which therapy was started for patients detected by screening from practices of CrescNet partners was significantly lower than that of patients not detected by screening. SD, standard deviation; GHD, growth hormone deficiency

### TABLE 2

<table>
<thead>
<tr>
<th>Center</th>
<th>1999</th>
<th>2000</th>
<th>2001</th>
<th>2002</th>
<th>2003</th>
<th>2004</th>
<th>2005</th>
</tr>
</thead>
<tbody>
<tr>
<td>1a former East German states, Leipzig total</td>
<td>10.11 (21)</td>
<td>10.72 (28)</td>
<td>9.76 (23)</td>
<td>8.51 (17)</td>
<td>8.47 (18)</td>
<td>7.81 (18)</td>
<td>6.50 (14)</td>
</tr>
<tr>
<td>1b former East German states, Leipzig after screening</td>
<td>—</td>
<td>10.21 (3)</td>
<td>9.57 (5)</td>
<td>6.77 (6)</td>
<td>6.97 (7)</td>
<td>8.45 (5)</td>
<td>5.02 (4)</td>
</tr>
<tr>
<td>2 former East German states</td>
<td>7.02 (4)</td>
<td>10.16 (8)</td>
<td>9.63 (10)</td>
<td>12.21 (14)</td>
<td>13.11 (10)</td>
<td>10.9 (16)</td>
<td>8.32 (10)</td>
</tr>
<tr>
<td>3 former East German states</td>
<td>11.22 (17)</td>
<td>9.75 (12)</td>
<td>13.86 (10)</td>
<td>10.38 (6)</td>
<td>10.59 (4)</td>
<td>6.11 (8)</td>
<td>7.02 (3)</td>
</tr>
<tr>
<td>4 former East German states</td>
<td>8.04 (1)</td>
<td>6.89 (3)</td>
<td>9.67 (3)</td>
<td>—</td>
<td>10.37 (3)</td>
<td>11.3 (3)</td>
<td>13.24 (3)</td>
</tr>
<tr>
<td>5 former East German states (2001–2005)</td>
<td>—</td>
<td>—</td>
<td>3.75 (4)</td>
<td>13.17 (1)</td>
<td>11.33 (4)</td>
<td>8.16 (7)</td>
<td>11.54 (4)</td>
</tr>
<tr>
<td>6 former West German states</td>
<td>9.04 (13)</td>
<td>12.1 (21)</td>
<td>10.05 (56)</td>
<td>10.05 (64)</td>
<td>10.87 (77)</td>
<td>10.85 (102)</td>
<td>11.72 (116)</td>
</tr>
<tr>
<td>7 former West German states</td>
<td>8.20 (50)</td>
<td>8.48 (59)</td>
<td>7.57 (38)</td>
<td>7.47 (35)</td>
<td>6.82 (22)</td>
<td>6.01 (20)</td>
<td>7.34 (22)</td>
</tr>
<tr>
<td>8 former West German states</td>
<td>10.40 (10)</td>
<td>9.86 (2)</td>
<td>9.64 (8)</td>
<td>8.76 (7)</td>
<td>12.58 (3)</td>
<td>11.14 (4)</td>
<td>10.02 (9)</td>
</tr>
<tr>
<td>9 former West German states (1999–2004)</td>
<td>6.10 (2)</td>
<td>6.70 (1)</td>
<td>4.99 (1)</td>
<td>4.26 (3)</td>
<td>12.64 (3)</td>
<td>6.76 (4)</td>
<td>—</td>
</tr>
</tbody>
</table>
In the Leipzig center 139 patients with GHD who had been newly placed on therapy could be included in the study over the course of the study. The following information was collected from the patients for the analysis: firstly, the age at the start of therapy, secondly, whether the referring practice was a partner in the CrescNet system or not, and thirdly, whether GHD in a patient in a CrescNet practice was detected primarily by screening of the CrescNet data or not.

Three infants were not included in the study whose growth hormone deficiency was verified and therapy initiated in the first year of life (mean age 0.59 ± 0.21 years) not due to a manifest growth disorder but to either hypoglycemia or indications of a familial genetic disorder. Nine patients with brain tumors (craniopharyngioma, medulloblastoma, neurofibromatosis) were also not included because most of them had been referred either only postoperatively from oncological treatment sites or for a second assessment by other pediatric endocrinologists (mean age: 10.92 ± 3.62 years).

To examine the question of whether any reduction in the age at the start of treatment could otherwise be observed over this period, the authors collected corresponding data from other treatment centers in Germany which have had a supraregional catchment area for many years and are specialist pediatric endocrinology centers and which were prepared to make their patient data available for comparisons. Centers in the former West German states and the former East German states were differentiated.

For the statistical tests we used the two-tailed t test, chi-square test (Tables 1 and 3) and linear regression (least squares method) (Figures 1 and 2), p values below 0.05 were considered statistically significant. A check of multiple errors was not planned because this is a descriptive study. SD is the standard deviation from the mean. Deviations from age- and sex-specific reference values were expressed as the SDS (standard deviation score, z-score).

**Results**

Table 1 shows that the patients from CrescNet practices began therapy earlier than those from non-CrescNet practices, although without significant differences (8.77 ± 3.40 versus 9.50 ± 3.78 years; p = 0.26). The differences between patients from CrescNet practices with and without previous screening on the other hand were significant (7.67 ± 3.21 versus 9.28 ± 3.39 years; p = 0.031). The difference between the patients from CrescNet practices with previous screening and patients from non-CrescNet practices was also significant (7.67 ± 3.21 versus 9.50 ± 3.78 years; p = 0.033) This means that these patients began treatment after preceding screening 1.8 years earlier on average.

The box plots in Figure 1 show the mean values with the 1st and 3rd quartile and the highest and lowest individual value of the age at the start of therapy according to the standards from 1999 to 2005. The circle indicates the mean value. The mean age at the start of therapy was initially (1999/2000) approximately 10.4 years and fell to 6.5 years by 2005. This drop in the age at the start of therapy is significant (p<0.001). Figure 2 shows that this trend affected patients from non-CrescNet practices (p = 0.012), patients from CrescNet practices (p<0.001), and patients after previous screening (p = 0.056) to a comparable degree. The black line in Figure 2 depicts the weighted mean of centers 2 to 9. The slight increase is not significant. A drop in the age at which therapy started was not recorded in the centers 2 to 9 in the former West and East German states (Table 2).

The mean age of all patients at the start of therapy was significantly higher in most centers than that in Leipzig (Table 3). Only in center 7 of the former West German states was the age at the start of therapy significantly lower compared to group 1a. In group 1b (patients after screening) the age at the start of therapy corresponded to the age in center 7 of the former West German states, although the difference was not significant.

**Update**

After separation of the CrescNet system from the University Hospital and its change to CrescNet gGmbH, the trend from 2006 to 2009 was as follows: In the Leipzig treatment centers for GHD, a total of 81 patients were newly placed on therapy. The mean age at the start of therapy exhibited slight fluctuations: 2006 = 8.23 ± 2.75 years (n = 21); 2007 = 7.26 ± 2.64 years (n = 22); 2008 = 8.29 ± 3.9 years (n = 10); 2009 = 7.18 ± 3.14 years (n = 28). This amounts to a total of 7.61 ± 3.0 years for this period with a median value of 6.64 years.
Discussion

That the success of substitution therapy with growth hormone is greater the earlier therapy is begun has been demonstrated in a number of publications (2–7). Blethen et al. take the clearest position on this issue (2). The other authors repeatedly identify the age at the start of therapy as one of the most important predictors of final adult height (3–7). Despite all the advances over the last two decades in terms of therapy safety and treatment modalities, even patients with growth hormone deficiency, that is, patients with the ‘classic’ therapy indication, lag behind the expected target height (7). During the attempt to further improve treatment procedures, prediction models for the response to human growth hormone (hGH) therapy were developed. Using comprehensive patient follow-up observations, it could be demonstrated that only a few clinical parameters are clearly correlated with the treatment outcome such as the severity of the growth hormone (GH) deficiency (measured using the maximal GH values that are reached in a GH stimulation test), the age at the start of the GH therapy, the duration of the hGH substitution, and the sex of the patients (4, 7). Interestingly, in most studies no correlation was found between the adult height and the level of the hGH substitution dose. There was also no correlation between the level of catch-up growth, which is empirically greatest after the start of therapy, and the age at the start of therapy. In total there is a height gain of +0.2 SDS per year of treatment on average; this is approximately 1.2 cm per year. It is clear from this that the only important clinical parameter that can be influenced by the therapists and improved is the age at the start of therapy.

In the efforts to lower the age at the start of therapy in the CrescNet system, successes could be achieved in the partnerships with the contractually bound medical practices, particularly after previous screening (Table 1). Between 1999 and 2005 the age at the start of therapy dropped significantly by about four years (Figure 1, Table 2). The previously mentioned average gain in height per year of treatment yields an additional gain in final height of about 5 cm. A decrease in the age at the start of therapy was not observed in this period in the treatment centers enlisted for comparison (Figure 2, Table 2).

Overall, the awareness of pediatricians for the problems associated with short stature has certainly increased as a result of their participation in the CrescNet program because the mean age at the start of therapy in the whole group and specifically in the group of patients after screening was significantly below that of most other treatment centers (Table 3). Treatment center 7 in the former West German states has the longest history of treating short-statured children of all the centers, and the center receives predominantly problematic cases that are discovered early from across a very large catchment area. Treatment center 5 of the former East German states with more recent data (2001 to 2005) is situated in Saxony and thanks to CrescNet
activities already benefit from the increased awareness of pediatricians to the problem of short stature.

The question of whether the trend towards earlier treatment described also has a favorable cost-benefit effect and a positive effect on final height cannot yet be determined because most patients in this study have not yet reached their final height.

Growth hormone deficiency served as a model disease in this study. Due to its rarity the case numbers were not very large. Additional currently recognized indications for growth hormone therapy include Ulrich-Turner syndrome, previously small for gestational age neonates (SGA) whose growth does not catch up, Prader-Willi syndrome, SHOX gene defects, and chronic renal failure. The CrescNet system is of course also suitable for early detection of other chronic diseases that are associated with disorders of growth and weight development and that do not become apparent predominantly due to other symptoms (such as disorders of pubertal development [18]). Finally, the clinical questions and objectives discussed here are also interesting for doctors in other specialties such as endocrinologists and andrologists.

Summary for practical application

Using the example of classic growth hormone deficiency, the descriptive analysis of data from different points of view indicated that the CrescNet system in the Leipzig treatment center enabled earlier detection of growth disorders than previously. The age at the start of therapy could be significantly decreased. By incorporating additional practices into the CrescNet system this effect should become apparent in all regions of Germany.

Acknowledgements

The authors are much obliged to the following colleagues for providing patient data: Prof. Jürgen Brämswig, Münster; Dr. Klaus Hartmann, Frankfurt/Main; Prof. Angela Hübnner, Dresden; Dr. Alexandra Keller, Leipzig; PD Dr. Klaus Motnik, Magdeburg; Prof. Michael Ranke and Dr. Roland Schweizer, Tübingen; Dr. Claudia Vilter, Jena; Dr. Christian Vogel, Chemnitz; Prof. Peter Willig, Hamburg.

We thank Ms Mandy Vogel for her help with the statistical calculations.

The not-for-profit organization CrescNet is supported by the following companies with donations in line with its charitable aims: Ferring Arzneimittel GmbH, Lilly Deutschland GmbH, Merck Serono GmbH, Novo Nordisk Pharma GmbH, Pfizer Pharma GmbH, Sandoz Pharmaceuticals GmbH.

Special thanks is due to the Leipzig University Hospital for maintaining and securing the CrescNet server in its data center.

KEY MESSAGES

Using the example of growth hormone deficiency, the descriptive analysis shows that the CrescNet system

- allows screening for growth disorders
- ensures growth disorders and their development are detected earlier
- decreases the age at diagnosis
- enables earlier treatment
- and an additional gain in final height of approximately 5 cm can be expected.

Conflict of interest statement

The donor funds are administered according to the not-for-profit status of CrescNet gGmbH. CrescNet gGmbH’s employees declare that no conflict of interest exists according to the guidelines of the International Committee of Medical Journal Editors. Professor Pfiffner received research funding from Eli Lilly, Ferring, and Pfizer and remuneration for lectures from Eli Lilly, Ferring, NovoNordisk, and Pfizer. He is a consultant to Eli Lilly.

Manuscript received on 30 July 2009, revised version accepted on 8 April 2010.

Translated from the original German by language & letters.

REFERENCES


Corresponding author
Prof. Dr. med. Eberhard Keller
CrescNet gGmbH
Philipp-Rosenthal-Str. 27b
04103 Leipzig, Germany
ruth.gausche@medizin.uni-leipzig.de